Breaking news on Bipolar disease
Overview Of Asenapine Data From Olympia Trial Program Presented At American Psychiatric Association Annual Meeting published
Fri, 09 May 2008 00:00:00 PDT
Schering-Plough Corporation (NYSE: SGP) announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washington, D.C., May 3-8. Data from the studies, involving patients with bipolar I disorder and schizophrenia, were presented in two oral presentations (Abstracts # 44 and # 80).
Problems Identified With Diagnosis Of Bipolar Disorder published
Wed, 07 May 2008 04:00:00 PDT
A new study by Rhode Island Hospital and Brown University researchers reports that fewer than half the patients previously diagnosed with bipolar disorder received a diagnosis of bipolar disorder based on a comprehensive, psychiatric diagnostic interview - -the Structured Clinical Interview for DSM-IV (SCID).
Benefits Of Omega 3s Still Unclear For Bipolar Disorder published
Wed, 23 Apr 2008 00:00:00 PDT
Despite intriguing findings that omega 3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega 3s are useful treatments for people with bipolar disorder, according to a review of recent studies.
Supplemental New Drug Application For RISPERDAL(R) CONSTA(R) Submitted To The FDA For The Treatment Of Frequently Relapsing Bipolar Disorder published
Wed, 16 Apr 2008 04:00:00 PDT
Alkermes, Inc. (NASDAQ: ALKS) announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a Supplemental New Drug Application (sNDA) for RISPERDAL® CONSTA® [(risperidone) Long-Acting Injection] to the U.S. Food and Drug Administration (FDA) seeking approval for adjunctive maintenance treatment to delay the occurrence of mood episodes in patients with frequently relapsing bipolar disorder (FRBD).
AstraZeneca Announces First Presentation Of Pivotal SEROQUEL XR(TM) Bipolar Studies published
Tue, 15 Apr 2008 01:00:00 PDT
New pivotal trial data from two clinical studies with SEROQUEL XR™ (quetiapine fumarate) once daily Extended Release Tablets were presented today at the Eighth International Review of Bipolar Disorder (IRBD) Conference in Copenhagen, Denmark.
European Marketing Authorization For Abilify - For Severe Manic Episodes In Bipolar I Disorder published
Mon, 14 Apr 2008 21:00:00 PDT
On April 8, 2008, the European Commission made a decision to allow thedrug ABILIFY® (aripiprazole) to be marketed. ABILIFY treats moderate tosevere manic episodes for patients with Bipolar I Disorder and it isdesigned to prevent new manic episodes in patients who experiencepredominately manic episodes.Before this decision, the European Committee for Medicinal Products forHuman Use (CHMP) issued a positive opinion in mid-February 2008.
Alcohol Dependence May Respond To Aripiprazole, Treatment For Bipolar Disorder And Schizophrenia. published
Sun, 06 Apr 2008 09:00:00 PDT
* Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. * A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol. * Future research will need to examine the beneficial versus the side effects of aripiprazole for treatment of alcohol dependence.
Famous Bipolar People Contest Raises Awareness, Encourages Research published
Mon, 31 Mar 2008 02:00:00 PDT
Famous bipolar people include some of the world's foremost musicians, actors, writers, composers and scientists. A new contest launched on YouTube uses the current interest in bipolar celebrities to raise awareness about bipolar disorder. The Famous Bipolar People Contest encourages research and reflection. According to contest organizers from www.bipolar-lives.
New Mouse Model Of Bipolar Disorder published
Wed, 12 Mar 2008 03:00:00 PDT
Bipolar Disorder (BPD or manic-depressive illness) is one of the most serious of all mental disorders, affecting millions of individuals worldwide. Affected individuals alternate between states of deep depression and mania. While depression is characterized by persistent and long-term sadness or despair, mania is a mental state characterized by great excitement, flight of ideas, a decreased need for sleep, and, sometimes, uncontrollable behavior, hallucinations, or delusions.
New Clues For Uncovering The Mysteries Of Mental Illness published
Wed, 12 Mar 2008 02:00:00 PDT
Scientists have discovered epigenetic changes (i.e. chemical changes to a gene that do not alter the DNA sequence) in individuals with schizophrenia and bipolar disorder. This is the first epigenome-wide investigation in psychiatric research, and this groundbreaking data may be a significant step on the journey to fully understanding major psychosis.Dr.
Breast Cancer Drug Tamoxifen May Decrease Mania Of Bipolar Disorder published
Wed, 05 Mar 2008 00:00:00 PDT
The drug tamoxifen is usually used to treat breast cancer, butresearchers say that it also may reduce symptoms of mania in peoplewith bipolar disorder. An article summarizing the small, three-weektrial of tamoxifen is published in Archives of GeneralPsychiatry.As a treatment for breast cancer, tamoxifen impacts the way in whichthe hormone estrogen works in the body. In addition, tamoxifen worksagainst the actions of the protein kinase C family of enzymes.
ABILIFY Approved For Acute Treatment Of Bipolar I Disorder In Patients 10 To 17 Years Old published
Mon, 03 Mar 2008 03:00:00 PDT
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY® (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).
Indiana U Study May Alter Approach To Psychiatric Treatment published
Tue, 26 Feb 2008 02:00:00 PDT
Indiana University School of Medicine researchers have isolated biomarkers in the blood that identify mood disorders, a breakthrough that may change the way bipolar illness is diagnosed and treated. The report will be published in the February 26 advance online edition of the journal Molecular Psychiatry.The panel of markers is present in differing amounts in individuals suffering from high or low mood states.
Alexza Initiates First Phase 3 Clinical Trial For AZ-004 (Staccato(R) Loxapine) published
Tue, 26 Feb 2008 00:00:00 PDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has initiated its first Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.
Bipolar Depression Licence Application For Seroquel(R) published
Mon, 18 Feb 2008 01:00:00 PDT
AstraZeneca has submitted an application to the Medicines and Healthcare products Regulatory Agency (MHRA) for a new licence for Seroquel(R) (quetiapine fumarate) in the UK for major depressive episodes in the framework of bipolar disorder. Quetiapine is currently licensed in the UK for the treatment of schizophrenia and manic episodes associated with bipolar disorder.1 Bipolar disorder affects about one in every 100 adults at some point in their life.
Astrazeneca Submits Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression, And Seroquel(R) For The Treatment Of Bipolar Depression published
Mon, 11 Feb 2008 14:00:00 PDT
AstraZeneca announced that the company has submitted applications in the European Union (EU) under the Mutual Recognition Procedure (MRP) for once-daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, seeking approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder. This follows two supplemental New Drug Applications (sNDAs) to the U.S.
Study Suggests Risperidone Long-Acting Injection Combined With Standard Treatment Helped Delay Time To Relapse In Patients With Bipolar Disorder published
Sun, 10 Feb 2008 00:00:00 PDT
Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.
ACADIA Announces Presentation Of Data On Pimavanserin Co-Therapy At The 14th Biennial Winter Workshop On On Schizophrenia And Bipolar Disorders published
Thu, 07 Feb 2008 03:00:00 PDT
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Murray Rosenthal, D.O.
Scientists Discover Chemical Signature Of Manic Depression published
Wed, 06 Feb 2008 04:00:00 PDT
People with manic depression have a distinct chemical signature in their brains, according to a new study. The research, published in the journal Molecular Psychiatry, may also indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to cause.
Study Suggests Risperidone Long Acting Injection Combined With Standard Treatment Helped Delay Time To Relapse In Patients With Bipolar Disorder published
Tue, 05 Feb 2008 00:00:00 PDT
Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.
New Analysis Demonstrates Efficacy Of Seroquel (Quetiapine Fumarate) Maintenance Treatment For Bipolar I Disorder published
Wed, 30 Jan 2008 16:00:00 PDT
Results from a combined analysis of two long term phase III clinical trials2,3 have shown that patients with bipolar I disorder who received treatment with quetiapine plus a mood stabiliser showed a 70% reduction in the risk of recurrence of a mood event (manic, mixed or depressed) compared to patients on a mood stabiliser alone (HR=0.30, P
New Analysis Highlights Potential Of SEROQUEL For Long-term Treatment Of Bipolar Disorder published
Mon, 28 Jan 2008 11:00:00 PDT
Results from a new analysis of two major clinical trials have shown that patients with bipolar disorder who received long-term treatment with SEROQUEL (quetiapine fumarate) plus a mood stabiliser were significantly less likely to have a mood event (manic, mixed or depressed) than patients on a mood stabiliser alone.
Psychological Interventions Are Effective In Mood Swings published
Thu, 17 Jan 2008 00:00:00 PDT
Jan Scott (Newcastle, UK) and Francesc Colom (Barcelona) have published a review of psychological interventions for bipolar disorder in the Jan 2008 issue of Psychotherapy and Psychosomatics.The aim of this review was to highlight gaps or limitations in applying evidence-based psychological therapies as an adjunct to medication in the management of bipolar disorders.
New Report Dispels Greatest Myths About Bipolar Disorder published
Mon, 14 Jan 2008 01:00:00 PDT
New free report reveals that many individuals misunderstand bipolar disorder and have bought into "bipolar lies." David Oliver, founder of Bipolar Central, has recently released a free report that uncovers and dispels various widely circulated myths about bipolar disorder. The report, entitled "10 Greatest Lies about Bipolar Disorder," outlines the top ten greatest lies about bipolar disorder--many of which are deadly--as well as the truth about managing bipolar disorder.
Most Psychiatric Patients Have More Than 1 Diagnosis, Study Finds published
Mon, 14 Jan 2008 01:00:00 PDT
A new study by Rhode Island Hospital researchers reports that the majority of 2,300 psychiatry outpatients had more than one disorder when seeking treatment, and more than one-third had at least three disorders. The study is published in the February 2008 edition of the journal Psychological Medicine.It is the largest study to date using standardized interviews to evaluate a wide range of psychiatric disorders in a general clinical outpatient practice.
)
|
|
